Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00269113 | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | completed | Phase 3 | 360 | Hoffmann-La RocheINDUSTRY | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00003414 | Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease | completed | Phase 3 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00398411 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells(MoxiProph) | completed | Phase 3 | 66 | University of CologneOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | terminated | Phase 3 | 48 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2015 | clinicaltrials |
| NCT01423500 | ALL-SCT BFM International- HSCT in Children and Adolescents With ALL(ALL-SCT-BFMi) | unknown | Phase 3 | 405 | St. Anna KinderkrebsforschungOTHER | 11 | Jun 26, 2015 | clinicaltrials |
| NCT01423747 | Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia | unknown | Phase 3 | 400 | St. Anna KinderkrebsforschungOTHER | 2 | Jun 26, 2015 | clinicaltrials |
| NCT02461121 | HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | completed | Phase 3 | 156 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00500240 | Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) | terminated | Phase 3 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00944008 | PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia(2009-009422-92) | terminated | Phase 3 | 7 | PETHEMA FoundationOTHER | 1 | May 8, 2015 | clinicaltrials |
| NCT00109538 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | terminated | Phase 3 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 1, 2015 | clinicaltrials |
| NCT02427919 | Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML(DeGREE) | unknown | Phase 2 / Phase 3 | 56 | Seoul St. Mary's HospitalOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT02423837 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma(BRiF) | unknown | Phase 3 | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | terminated | Phase 3 | 129 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00117598 | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)(OPTIMAL) | completed | Phase 3 | 169 | PfizerINDUSTRY | 18 | Mar 30, 2015 | clinicaltrials |
| NCT00434161 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | completed | Phase 3 | 281 | Swedish Orphan BiovitrumINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00064038 | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 3 | 198 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00838357 | A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).(PREDICT) | completed | Phase 3 | 118 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Mar 24, 2015 | clinicaltrials |
| NCT00002548 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | completed | Phase 3 | 899 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | terminated | Phase 3 | 19 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00005866 | S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia | completed | Phase 3 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Mar 6, 2015 | clinicaltrials |
| NCT00416273 | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 217 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416208 | Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | completed | Phase 3 | 154 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 21, 2015 | clinicaltrials |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | terminated | Phase 3 | 800 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00613457 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia(AIEOP LLA 2000) | completed | Phase 3 | 2,039 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 0 | Jan 14, 2015 | clinicaltrials |
| NCT02336386 | CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma | unknown | Phase 3 | 100 | Beijing Chao Yang HospitalOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01767714 | Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation | completed | Phase 3 | 100 | SanofiINDUSTRY | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01800643 | Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | Phase 2 / Phase 3 | 100 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT01650805 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | terminated | Phase 3 | 307 | Ariad PharmaceuticalsINDUSTRY | 24 | Nov 17, 2014 | clinicaltrials |
| NCT02288741 | Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy(DSMM-II) | completed | Phase 3 | 549 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Nov 11, 2014 | clinicaltrials |
| NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | completed | Phase 3 | 50 | OncotherapeuticsINDUSTRY | 1 | Nov 6, 2014 | clinicaltrials |
| NCT00123487 | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 638 | Bristol-Myers SquibbINDUSTRY | 32 | Nov 3, 2014 | clinicaltrials |
| NCT00322101 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | completed | Phase 3 | 25 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 31, 2014 | clinicaltrials |
| NCT00795756 | Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 145 | Northern Italy Leukemia GroupOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02238873 | Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma | unknown | Phase 3 | 300 | Rabin Medical CenterOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT00059839 | Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | completed | Phase 3 | 129 | Children's Oncology GroupNETWORK | 5 | Sep 22, 2014 | clinicaltrials |
| NCT00109031 | Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | completed | Phase 3 | 47 | Swedish Orphan BiovitrumINDUSTRY | 0 | Sep 15, 2014 | clinicaltrials |
| NCT01609010 | A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma | completed | Phase 3 | 313 | Hoffmann-La RocheINDUSTRY | 3 | Sep 8, 2014 | clinicaltrials |
| NCT00583323 | Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET | completed | Phase 3 | 60 | Mayo ClinicOTHER | 0 | Aug 21, 2014 | clinicaltrials |
| NCT00854568 | Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL | completed | Phase 3 | 398 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00813150 | Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma | completed | Phase 3 | 96 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Aug 15, 2014 | clinicaltrials |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | terminated | Phase 3 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00002618 | Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma | completed | Phase 3 | 242 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00002757 | TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma | completed | Phase 3 | 1,148 | Children's Oncology GroupNETWORK | 2 | Jul 24, 2014 | clinicaltrials |
| NCT00005578 | Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease | completed | Phase 3 | 219 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT02070523 | Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: | unknown | Phase 3 | 200 | Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.OTHER | 1 | Jul 8, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2015source: clinicaltrials